RESUMO
PURPOSE OF REVIEW: Diabetes is the most prevalent long-term metabolic condition and its incidence continues to increase unabated. Patients with diabetes are overrepresented in the surgical population. It has been well recognized that poor perioperative diabetes control is associated with poor surgical outcomes. The outcomes are worst for those people who were not recognized as having hyperglycaemia. RECENT FINDINGS: Recent work has shown that preoperative recognition of diabetes and good communication between the clinical teams at all stages of the patient pathway help to minimize the potential for errors, and improve glycaemic control. The stages of the patient journey start in primary care and end when the patient goes home. The early involvement of the diabetes specialist team is important if the glycated haemoglobin is more than 8.5%, and advice sought if the preoperative assessment team is not familiar with the drug regimens. To date the glycaemic targets for the perioperative period have remained uncertain, but recently a consensus is being reached to ensure glucose levels remain between 108 and180âmg/dl (6.0 and 10.0âmmol/l). There have been a number of ways to achieve these - primarily by manipulating the patients' usual diabetes medications, to also allow day of surgery admission. SUMMARY: glycaemic control remains an important consideration in the surgical patient.
Assuntos
Diabetes Mellitus/sangue , Hemoglobinas Glicadas/análise , Hiperglicemia/sangue , Hipoglicemia/sangue , Assistência Perioperatória/métodos , Procedimentos Cirúrgicos Operatórios/efeitos adversos , Glicemia/análise , Glicemia/efeitos dos fármacos , Estado Terminal , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/cirurgia , Glucose/uso terapêutico , Humanos , Hiperglicemia/diagnóstico , Hiperglicemia/tratamento farmacológico , Hiperglicemia/cirurgia , Hipoglicemia/diagnóstico , Hipoglicemia/tratamento farmacológico , Hipoglicemia/cirurgia , Hipoglicemiantes/uso terapêutico , Bombas de Infusão Implantáveis , Insulina/uso terapêutico , Náusea e Vômito Pós-Operatórios/sangue , Náusea e Vômito Pós-Operatórios/complicações , Náusea e Vômito Pós-Operatórios/tratamento farmacológico , Cloreto de Potássio/uso terapêutico , Estresse Psicológico/sangue , Resultado do TratamentoRESUMO
OBJECTIVE: Our objective was to evaluate the significance of pre-hospital and post-operative serum potassium level monitoring and hypokalemia intervention in laparotomy patients with hypokalemia. METHOD: A total of 118 laparotomy patients with hypokalemia were randomly divided into an intervention group (N = 60) and a control group (N = 58). Blood samples were collected for measurement of potassium levels at various time points (pre-admission, admission, 24 h and 48 h post-operation) for both groups. Hypokalemia interventions were administered to patients in the intervention group in the pre-admission period and the post-operative period. Visceral dynamics were assessed after laparotomy in both groups. RESULT: Average serum potassium levels at admission, time period of drinking, and time of first bowel sound after laparotomy differed significantly (p < 0.001) between the two groups. Average serum potassium levels, first time of defecation, urination, and ambulation at 24 h and 48 h post-operation differed significantly (p < 0.05) between the two groups. CONCLUSION: An optimal pathway of serum potassium monitoring not only saves limited ward space but also allows for early correction of hypokalemia in patients undergoing laparotomy.
Assuntos
Procedimentos Cirúrgicos Eletivos/reabilitação , Hipopotassemia/diagnóstico , Laparotomia/reabilitação , Cuidados Pós-Operatórios/métodos , Complicações Pós-Operatórias/diagnóstico , Potássio/sangue , Adolescente , Adulto , Idoso , Biomarcadores/sangue , Dietoterapia , Suplementos Nutricionais , Feminino , Humanos , Hipopotassemia/sangue , Hipopotassemia/etiologia , Hipopotassemia/terapia , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/sangue , Complicações Pós-Operatórias/terapia , Cloreto de Potássio/uso terapêutico , Cuidados Pré-Operatórios/métodos , Recuperação de Função Fisiológica , Resultado do Tratamento , Adulto JovemRESUMO
INTRODUCTION: As even small concentrations of acetate in the plasma result in pro-inflammatory and cardiotoxic effects, it has been removed from renal replacement fluids. However, Plasma-Lyte 148 (Plasma-Lyte), an electrolyte replacement solution containing acetate plus gluconate is a common circuit prime for cardio-pulmonary bypass (CPB). No published data exist on the peak plasma acetate and gluconate concentrations resulting from the use of Plasma-Lyte 148 during CPB. METHODS: Thirty adult patients were systematically allocated 1:1 to CPB prime with either bicarbonate-balanced fluid (24 mmol/L bicarbonate) or Plasma-Lyte 148. Arterial blood acetate, gluconate and interleukin-6 (IL-6) levels were measured immediately before CPB (T1), three minutes after CPB commencement (T2), immediately before CPB separation (T3), and four hours post separation (T4). RESULTS: Acetate concentrations (normal 0.04 to 0.07 mmol/L) became markedly elevated at T2, where the Plasma-Lyte group (median 3.69, range (2.46 to 8.55)) exceeded the bicarbonate group (0.16 (0.02 to 3.49), P < 0.0005). At T3, levels had declined but the differential pattern remained apparent (Plasma-Lyte 0.35 (0.00 to 1.84) versus bicarbonate 0.17 (0.00 to 0.81)). Normal circulating acetate concentrations were not restored until T4. Similar gluconate concentration profiles and inter-group differences were seen, with a slower T3 decay. IL-6 increased across CPB, peaking at T4, with no clear difference between groups. CONCLUSIONS: Use of acetate containing prime solutions result in supraphysiological plasma concentrations of acetate. The use of acetate-free prime fluid in CPB significantly reduced but did not eliminate large acetate surges in cardiac surgical patients. Complete elimination of acetate surges would require the use of acetate free bolus fluids and cardioplegia solutions. TRIAL REGISTRATION: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12610000267055.
Assuntos
Acetatos/sangue , Bicarbonatos/uso terapêutico , Ponte Cardiopulmonar/métodos , Gluconatos/sangue , Interleucina-6/sangue , Idoso , Feminino , Gluconatos/uso terapêutico , Humanos , Período Intraoperatório , Soluções Isotônicas , Cloreto de Magnésio/uso terapêutico , Masculino , Pessoa de Meia-Idade , Período Pós-Operatório , Cloreto de Potássio/uso terapêutico , Acetato de Sódio/uso terapêutico , Cloreto de Sódio/uso terapêutico , Fatores de Tempo , Resultado do TratamentoRESUMO
Placenta previa (PP), with a frequency of 5-7% in the second trimester, is considered one of the most important causes of obstetric hemorrhage. Surgical curettage is the classically recommended method to perform a midtrimester termination of pregnancy (TOP) in the presence of PP. Recent clinical reports suggest that induction of delivery is possible in these cases, but no information on mifepristone-misoprostol regimen is available. We present 2 cases of mifepristone-misoprostol midtrimester TOP with a diagnosis of complete PP. In both cases, a preinduction feticide was performed. Neither of the 2 cases presented a significant maternal bleeding. This report is relevant considering that this regimen is the most widely used and generally reported as the safest and most effective medical midtrimester TOP method.
Assuntos
Abortivos não Esteroides/uso terapêutico , Aborto Terapêutico/métodos , Mifepristona/uso terapêutico , Misoprostol/uso terapêutico , Placenta Prévia , Abortivos não Esteroides/administração & dosagem , Administração Oral , Feminino , Humanos , Mifepristona/administração & dosagem , Misoprostol/administração & dosagem , Hemorragia Pós-Parto/prevenção & controle , Cloreto de Potássio/administração & dosagem , Cloreto de Potássio/farmacologia , Cloreto de Potássio/uso terapêutico , Gravidez , Segundo Trimestre da GravidezRESUMO
Sjogren syndrome (SS) is a systemic autoimmune disorder with predominant exocrine gland involvement leading to sicca symptoms. Among extraglandular manifestations, renal disease is the most common. Tubular interstitial nephritis and renal tubular acidosis (RTA) are the common presentations. Mild hypokalemia associated with distal RTA is common in SS, however, severe hypokalemia causing paralysis is unusual. We report the case of a 26-year-old female who presented with hypokalemic paralysis. On evaluation, distal RTA was diagnosed. Further evaluation showed positive SS-a/SS-b antibodies in high titer, which confirms the diagnosis of primary SS. Our report illustrates that SS is a rare but important cause of hypokalemic paralysis.
Résumé syndrome de Sjogren (SS) est une maladie auto-immune systémique avec une atteinte prédominante des glandes exocrines entraînant des symptômes de sicca. Parmi manifestations extraglandulaires, la maladie rénale est la plus courante. La néphrite interstitielle tubulaire et l'acidose tubulaire rénale (RTA) sont les présentations. Une hypokaliémie légère associée à un RTA distal est courante dans les SS, cependant, une hypokaliémie sévère provoquant une paralysie est inhabituelle. Nous rapportons le cas d'une femme de 26 ans qui présentait une paralysie hypokaliémique. À l'évaluation, un RTA distal a été diagnostiqué. Plus loin l'évaluation a montré des anticorps SS-a / SS-b positifs à titre élevé, ce qui confirme le diagnostic de SS primaire. Notre rapport montre que SS est un cause rare mais importante de paralysie hypokaliémique.
Assuntos
Acidose Tubular Renal/complicações , Hipopotassemia/diagnóstico , Paralisia/etiologia , Síndrome de Sjogren/diagnóstico , Administração Intravenosa , Administração Oral , Adulto , Anticorpos Antinucleares/sangue , Bicarbonatos/administração & dosagem , Bicarbonatos/uso terapêutico , Feminino , Humanos , Hipopotassemia/tratamento farmacológico , Paralisia Periódica Hiperpotassêmica , Cloreto de Potássio/administração & dosagem , Cloreto de Potássio/uso terapêutico , Citrato de Potássio/administração & dosagem , Citrato de Potássio/uso terapêutico , Compostos de Potássio/administração & dosagem , Compostos de Potássio/uso terapêutico , Síndrome de Sjogren/etiologia , Resultado do TratamentoRESUMO
We describe a 37-year-old man with a 4-month history of episodic muscular weakness, involving mainly lower-limbs. Hypokalemia was documented in one episode and managed with intravenous potassium chloride. Hyperthyroidism was diagnosed 4 months after onset of attacks because of mild symptoms. The patient was subsequently diagnosed as having thyrotoxic periodic paralysis associated with Graves' disease. Treatment with propranolol and methimazol was initiated and one year later he remains euthyroid and symptom free. Thyrotoxic periodic paralysis is a rare disorder, especially among Caucasians, but it should always be considered in patients with acute paralysis and hypokalemia, and thyroid function should be evaluated.
Assuntos
Hipertireoidismo/diagnóstico , Hipopotassemia/diagnóstico , Paralisias Periódicas Familiares/diagnóstico , Adulto , Doença de Graves/complicações , Humanos , Hipertireoidismo/complicações , Hipertireoidismo/terapia , Hipopotassemia/complicações , Hipopotassemia/terapia , Masculino , Metimazol/administração & dosagem , Paralisias Periódicas Familiares/complicações , Paralisias Periódicas Familiares/terapia , Cloreto de Potássio/uso terapêutico , Propranolol/administração & dosagem , Resultado do TratamentoRESUMO
OBJECTIVE: To explore the safety and clinical efficacy of intravenous infusion of concentrated potassium chloride using micro-pumps in critically ill patients with hypokalemia. METHODS: One hundred and twenty-eight critically ill patients with hypokalemia, the endogenous creatinine clearance rate over 0.5 ml/second and the urine output over 50 ml/hour were randomly divided into the therapy group (n=64) and the control group (n=64). Patients in therapy group received 1,208 mmol/L (9%) KCl, while those in the control group received 201 mmol/L (1.5%) potassium chloride, intravenously with the aid of a micro-pump, with hourly equal quantity of KCl in both groups. Patients in both groups were monitored strictly, and the potassium infusion was stopped whenever the serum potassium exceeded or equal to 3.5 mmol/L. RESULTS: It took (15.55+/-3.22) hours and (14.18+/-4.93) hours for the therapy group and the control group to correct the hypokalemia respectively, and there was no significant difference (P>0.05). Potassium infusion brought larger amount of fluid in the control group than the therapy group [(124.36+/-25.79) ml vs. (680.83+/-236.70) ml, P<0.01]. All patients tolerated the infusion without evidence of hemodynamic change, hyperkalemia or acute heart dysfunction. For all the patients, renal function did not throw significant influence on the potassium infusion time. An inverse correlation was observed between preinfusion potassium concentration and the quantity of potassium infused (r= -0.259, P<0.01). CONCLUSION: Under meticulous monitoring, it is safe and effective to infuse concentrated potassium for the critically ill patients with hypokalemia. This strategy can also be followed in patients with mild renal dysfunction but without oliguria or anuria under careful monitoring.
Assuntos
Hipopotassemia/tratamento farmacológico , Cloreto de Potássio/administração & dosagem , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Estado Terminal , Feminino , Humanos , Bombas de Infusão , Masculino , Pessoa de Meia-Idade , Cloreto de Potássio/uso terapêutico , Resultado do Tratamento , Adulto JovemRESUMO
Hypokalaemia can be treated with potassium chloride mixture. Some mixtures contain liquorice extract (glycyrrhizin) as a supplement to improve taste. Glycyrrhizin can cause pseudohyperaldosteronism and thereby result in hypertension and hypokalaemia. We here present a case where treatment with potassium chloride mixture causes hypertension and hypokalaemia in a 50-year-old woman. After unravelling differential diagnosis, the potassium chloride mixture was stopped. After the discontinuation, the patient's blood pressure was well managed and the potassium levels normalised.
Assuntos
Glycyrrhiza/efeitos adversos , Ácido Glicirrízico/efeitos adversos , Hiperaldosteronismo/induzido quimicamente , Hipertensão/tratamento farmacológico , Hipopotassemia/induzido quimicamente , Cloreto de Potássio/efeitos adversos , Verapamil/uso terapêutico , Diagnóstico Diferencial , Feminino , Ácido Glicirrízico/uso terapêutico , Humanos , Hiperaldosteronismo/sangue , Hiperaldosteronismo/diagnóstico , Hipertensão/sangue , Hipertensão/diagnóstico , Hipopotassemia/sangue , Hipopotassemia/diagnóstico , Hipopotassemia/etiologia , Pessoa de Meia-Idade , Potássio/sangue , Cloreto de Potássio/farmacologia , Cloreto de Potássio/uso terapêutico , Resultado do TratamentoRESUMO
The treatment of ectopic pregnancies has evolved from a purely surgical route with routine removal of the fallopian tube to one with multiple options. Medical treatment can be administered systemically or via local injection. Local delivery of chemotherapeutic agents is a safe and proven modality that is especially indicated for pregnancies in which a laparoscopic approach is not ideal and systemic therapy either has failed or is not desired. Local therapy has the potential to document immediately the cessation of fetal heart activity. Nontubal ectopic pregnancies may be ideally suited to local therapy, especially when there is a fetal heart present. Transvaginal ultrasound is the preferred mode for guidance and laparoscopic guidance has a limited role. Although a multitude of agents have been proposed, methotrexate, KCl, and hyperosmolar glucose are the most widely used and readily available. Local therapy has an important place in the armamentarium of the treatment of ectopic pregnancies.
Assuntos
Gravidez Ectópica/tratamento farmacológico , Gravidez Ectópica/cirurgia , Abortivos não Esteroides/administração & dosagem , Abortivos não Esteroides/uso terapêutico , Danazol/administração & dosagem , Danazol/uso terapêutico , Etoposídeo/administração & dosagem , Etoposídeo/uso terapêutico , Tubas Uterinas/patologia , Feminino , Glucose/administração & dosagem , Glucose/uso terapêutico , Humanos , Laparoscopia , Metotrexato/administração & dosagem , Metotrexato/uso terapêutico , Cloreto de Potássio/administração & dosagem , Cloreto de Potássio/uso terapêutico , Gravidez , Gravidez Ectópica/diagnóstico por imagem , Gravidez Ectópica/prevenção & controle , Prostaglandinas/administração & dosagem , Prostaglandinas/uso terapêutico , Salpingostomia , Ultrassonografia Pré-Natal/métodosAssuntos
Carboidratos da Dieta , Hipertireoidismo/complicações , Hipopotassemia/etiologia , Paralisia Periódica Hipopotassêmica/etiologia , Paralisia/etiologia , Tireotoxicose/complicações , Doença Aguda , Antagonistas Adrenérgicos beta/uso terapêutico , Antitireóideos/uso terapêutico , Doença de Graves/complicações , Humanos , Hipertireoidismo/patologia , Hipertireoidismo/cirurgia , Hipopotassemia/diagnóstico , Hipopotassemia/tratamento farmacológico , Paralisia Periódica Hipopotassêmica/tratamento farmacológico , Masculino , Metimazol/uso terapêutico , Debilidade Muscular/etiologia , Periodicidade , Cloreto de Potássio/uso terapêutico , Propranolol/uso terapêutico , Tireoidectomia , Tireotoxicose/sangue , Tireotoxicose/diagnóstico , Tireotoxicose/tratamento farmacológico , Resultado do Tratamento , Adulto JovemRESUMO
Background: Severe cholera is a life-threatening illness of hypovolemic shock and metabolic acidosis due to rapid and profuse diarrheal fluid loss. Emergency life-saving therapy is i.v. saline, optionally supplemented with potassium and alkali to correct the fluid deficit, potassium losses and acidosis. After this initial rehydration, for the next 2 days ongoing stool losses are replaced with oral rehydration solution (ORS), which contains sodium chloride, potassium and alkali together with glucose or rice powder as a source of glucose to serve as a carrier for sodium. Results: In actual field trials, antibiotics are given to reduce fluid requirements, but large volumes averaging about 7 liters of i.v. fluid followed by about 14 liters of ORS have been given to adult patients. Disturbing trends during therapy have included overhydration, hyponatremia and polyuria. Conclusions: It is suggested that stool output and fluid requirements could be reduced, if borne out in future research, by avoiding overhydration by restricting ORS intake to match stool output and promoting intestinal reabsorption of luminal fluid by early introduction of glucose without salts into the intestine, more gradual correction of dehydration, giving mineralocorticoid and vasopressin, and infusing glucose or short-chain fatty acids into the proximal colon.
Assuntos
Antidiarreicos/uso terapêutico , Cólera/complicações , Defecação , Desidratação/terapia , Diarreia/terapia , Hidratação/métodos , Antidiarreicos/administração & dosagem , Antidiarreicos/farmacologia , Bicarbonatos/administração & dosagem , Bicarbonatos/química , Bicarbonatos/uso terapêutico , Cólera/terapia , Defecação/efeitos dos fármacos , Desidratação/etiologia , Diarreia/tratamento farmacológico , Diarreia/etiologia , Diarreia/prevenção & controle , Fezes , Hidratação/efeitos adversos , Glucose/administração & dosagem , Glucose/química , Glucose/uso terapêutico , Humanos , Hiponatremia/etiologia , Hiponatremia/prevenção & controle , Poliúria/etiologia , Poliúria/prevenção & controle , Cloreto de Potássio/administração & dosagem , Cloreto de Potássio/química , Cloreto de Potássio/uso terapêutico , Cloreto de Sódio/administração & dosagem , Cloreto de Sódio/química , Cloreto de Sódio/uso terapêuticoRESUMO
The efficiency of myocardial protection with cold crystalloid cardioplegia (CC) during operations on the heart under total ischemia and extracorporeal circulation was studied. Two hundred and fifty patients who underwent prosthetic or plastic repair of the aortic and mitral valves or plastic repair of the tricuspid valve were examined. Group 1 comprised 218 patients in whom the myocardium was protected with Konsol solution ("Biofarm "research-and-production enterprise, Russia); Group 2 included 32 patients in whom Custodiol solution ("Dr Franz Kohler Chemia GMBH", Germany). The volume of the Konsol solution required for CC was 400-2000 ml, with the duration of myocardial ischemia (MI) being 75 +/- 33 min; that of the Custodiol was 2000-4000 ml, with the duration of MI being 80 +/- 22 min. The used algorithm of administration of the solutions provided a persistent cardioplegic effect in both groups. After aortic declamping, there was a spontaneous recovery of cardiac performance in 84 and 40% in Groups 1 and 2, respectively. In the reperfusion period (RP), no significant differences were found in the basic hemodynamic parameters (heart rate, blood pressure, and central venous pressure) in both groups. After defect correction, cardiac output equally increased in both groups. The groups did not differ in the rate of inotropic support either. In RP, transient cardiac rhythm and conduction disturbances occurred in 19 and 28% in Groups 1 and 2, respectively.
Assuntos
Soluções Cardioplégicas/uso terapêutico , Doenças das Valvas Cardíacas/cirurgia , Traumatismo por Reperfusão Miocárdica/prevenção & controle , Soluções Cardioplégicas/administração & dosagem , Circulação Coronária/efeitos dos fármacos , Feminino , Glucose/administração & dosagem , Glucose/uso terapêutico , Humanos , Período Intraoperatório , Masculino , Manitol/administração & dosagem , Manitol/uso terapêutico , Pessoa de Meia-Idade , Miocárdio/metabolismo , Cloreto de Potássio/administração & dosagem , Cloreto de Potássio/uso terapêutico , Procaína/administração & dosagem , Procaína/uso terapêutico , Resultado do TratamentoAssuntos
Abortivos não Esteroides/uso terapêutico , Aborto Terapêutico/métodos , Colo/diagnóstico por imagem , Metotrexato/uso terapêutico , Cloreto de Potássio/uso terapêutico , Gravidez Ectópica/tratamento farmacológico , Adulto , Feminino , Humanos , Gravidez , Gravidez Ectópica/diagnóstico por imagem , Resultado do TratamentoRESUMO
Bartter syndrome is an autosomal recessive renal tubulopathy that presents with hypokalemic, hypochloremic metabolic alkalosis associated with increased urinary loss of sodium, potassium, calcium and chloride. There is hyperreninemia and hyperaldosteronemia but normotension. A full term male neonate was referred at 20-day of age with features of sepsis and respiratory distress. He was evaluated and managed as case of septicemia with all supportive paraphernalia including mechanical ventilation. Investigations revealed electrolytes imbalance and metabolic alkalosis suggestive of Neonatal Bartter Syndrome (NBS). Raised aldosterone and renin levels confirmed the diagnosis. Electrolyte imbalance was corrected with fluids and indomethacin, treated successfully, discharged and parents counseled. He was thriving well at 9 months of age. Another 2 months old male baby presented with recurrent episodes of lethargy with dehydration and failure to gain weight. Investigations confirmed the diagnosis of NBS. He was also successfully treated with same medication. We report these 2 cases because of the rarity of NBS, presentation of which may mimic common illnesses like sepsis and gastroenteritis.
Assuntos
Síndrome de Bartter/complicações , Síndrome de Bartter/diagnóstico , Desequilíbrio Hidroeletrolítico/etiologia , Aldosterona/sangue , Anti-Inflamatórios não Esteroides/uso terapêutico , Síndrome de Bartter/tratamento farmacológico , Biomarcadores/sangue , Humanos , Indometacina/uso terapêutico , Lactente , Recém-Nascido , Doenças do Recém-Nascido/diagnóstico , Masculino , Cloreto de Potássio/uso terapêutico , Doenças Raras/complicações , Renina/sangue , Cloreto de Sódio na Dieta/uso terapêutico , Resultado do Tratamento , Desequilíbrio Hidroeletrolítico/terapiaRESUMO
OBJECTIVE: To compare the efficacy of an oral rehydration solution (ORS) containing short polymers of glucose derived from rice (Amylyte-ORS) and five times the caloric density of current ORS to the standard glucose-ORS (World Health Organization [WHO] = ORS) in the treatment of acute diarrhea in children. METHODS: The rice ORS (Amylyte-ORS) was obtained by adding thermophilic amylase (252,500 MW units) and salts (1.5 g NaCl, 600 mg KCl, and 150 mg CaCl2) to 100 g rice and boiling for 10 minutes in 500 mL water. This yields 250 mL Amylyte-ORS, which contains 92% to 96% short-chain glucose polymers, three to nine molecules in length, and provides 425 kcal/L, compared to 80 kcal/L for the WHO-ORS. One hundred forty-four male children, 4 months to 3 years of age, presenting with acute diarrhea and mild, moderate, or severe dehydration, were assigned by random allocation to receive either WHO-ORS or Amylyte-ORS. Data from 127 children were analyzed (57 received the WHO-ORS and 70 the Amylyte-ORS). Two children given Amylyte-ORS and 15 given the WHO-ORS were not included in the analysis because of improperly collected data or lost urine or fecal specimens. None were given antibiotics during the study. Free water and feeding were allowed after the children were rehydrated. RESULTS: The clinical characteristics of the children in the two treatment groups were comparable. Five children who received the WHO-ORS and three children given Amylyte-ORS were treatment failures. Amylyte-ORS reduced diarrhea duration by 15% (41.4 +/- 2.5 vs 34.7 +/- 1.8 hours; P < .03) compared to the WHO-ORS, regardless of the severity of dehydration. In the Amylyte-treated group, ORS requirements were significantly less (234 +/- 15.2 vs 295 +/- 17.6 mL/kg; P < .01) and weight gain was significantly more (367.7 +/- 45.1 vs 199.2 +/- 38.2 g; P < .01) than in those given the WHO-ORS. The net intestinal fluid balance and total body fluid balance were similar in the two groups. CONCLUSIONS: Amylyte-ORS effectively rehydrates children with acute diarrhea, reduces diarrhea duration, decreases ORS requirements, and improves weight gain compared to the WHO-ORS.
Assuntos
Desidratação/terapia , Diarreia Infantil/terapia , Diarreia/terapia , Hidratação , Glucose , Oryza , Soluções para Reidratação/uso terapêutico , Doença Aguda , Amilases , Bicarbonatos/química , Bicarbonatos/uso terapêutico , Pré-Escolar , Glucose/química , Glucose/uso terapêutico , Humanos , Lactente , Masculino , Cloreto de Potássio/química , Cloreto de Potássio/uso terapêutico , Soluções para Reidratação/química , Cloreto de Sódio/química , Cloreto de Sódio/uso terapêutico , Fatores de Tempo , Resultado do Tratamento , Equilíbrio Hidroeletrolítico , Aumento de PesoRESUMO
Sixteen patients with diuretic-induced hypokalemia underwent 24-hour ambulatory electrocardiographic monitoring during and after correction of hypokalemia. Plasma potassium averaged 2.83 +/- 0.08 mEq/liter before and 3.73 +/- 0.06 mEq/liter after correction with potassium chloride, triamterene or both. Premature atrial contractions decreased in 6 patients, increased in 6 and remained unchanged in 4. There was no improvement in ventricular ectopic activity after plasma potassium correction. Ventricular ectopic activity improved in 5 patients, worsened in 10 and remained unchanged in 1. Ventricular tachycardia was not observed in either phase. Plasma magnesium remained normal throughout. The investigators conclude that in patients with uncomplicated hypertension, correction of diuretic-induced hypokalemia does not significantly reduce the occurrence of spontaneous atrial or ventricular ectopic activity.
Assuntos
Arritmias Cardíacas/prevenção & controle , Diuréticos/efeitos adversos , Hipertensão/tratamento farmacológico , Hipopotassemia/induzido quimicamente , Adulto , Idoso , Assistência Ambulatorial , Anti-Hipertensivos/uso terapêutico , Complexos Cardíacos Prematuros/prevenção & controle , Clortalidona/efeitos adversos , Eletrocardiografia , Humanos , Hidroclorotiazida/efeitos adversos , Hipopotassemia/tratamento farmacológico , Pessoa de Meia-Idade , Monitorização Fisiológica , Potássio/sangue , Cloreto de Potássio/uso terapêutico , Triantereno/uso terapêuticoRESUMO
Sixty patients undergoing cardiopulmonary bypass (CPB) with the Travenol 6 L. variflow oxygenator bag and total hemodilution with Ringer's lactate with 5 per cent dextrose were observed for their variances in potassium (K+) levels and the degree of potassium replacement. We have seen that the potassium level drops before CPB bypass in relation to the preadmission to the operating room potassium level. During bypass the level rises and following bypass it once again falls to be preceded by a rise after the first 24 hour postoperative period...
Assuntos
Ponte Cardiopulmonar/métodos , Hipopotassemia/prevenção & controle , Cloreto de Potássio/uso terapêutico , Adulto , Idoso , Glicosídeos Digitálicos/uso terapêutico , Diuréticos/uso terapêutico , Humanos , Pessoa de Meia-Idade , Potássio/sangue , Potássio/urina , Fibrilação Ventricular/prevenção & controleRESUMO
Experimentally, creatine phosphate (CP) added to St. Thomas' Hospital cardioplegic solution (STH) improved post-ischaemic recovery of cardiac function in the rat heart. We investigated the effect of adding CP (10.0 mmol/l) to STH. Fifty open-heart surgery patients were randomized into control (STH) and treated (STH + CP) groups (25 per group). Patients underwent (a) monitoring for peri- and postoperative arrhythmias (48-h Holter monitoring). (b) quantitative birefringence assessment of intraoperative myocardial protection in left and right ventricular biopsies sampled at start of bypass (pre-isch.), end of bypass (end-isch.) and after 10 min reperfusion (post-isch.), and (c) measurement of serum creatine kinase-MB isozyme (CK-MB) values for up to 4 days postoperatively; results were assessed with respect to (d) haemodynamics and postoperative clinical outcome. Inotropic support (adrenaline) was required in three patients (12%) from each group; no patient died. All patients required defibrillation, and the number of direct current shocks required for sinus rhythm was the same in each group. The occurrence and incidence of reperfusion-induced arrhythmias were the same in both groups. Serum CK and CK-MB values were similar throughout the sampling period in both groups of patients; one patient in the control group had raised CK-MB levels postoperatively, but perioperative infarction was not indicated by the electrocardiogram.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Arritmias Cardíacas/prevenção & controle , Soluções Cardioplégicas/uso terapêutico , Parada Cardíaca Induzida , Fosfocreatina/uso terapêutico , Adulto , Idoso , Aorta/cirurgia , Bicarbonatos/administração & dosagem , Bicarbonatos/uso terapêutico , Cloreto de Cálcio/administração & dosagem , Cloreto de Cálcio/uso terapêutico , Soluções Cardioplégicas/administração & dosagem , Ponte de Artéria Coronária , Creatina Quinase/sangue , Eletrocardiografia , Parada Cardíaca Induzida/métodos , Valvas Cardíacas/cirurgia , Humanos , Isoenzimas , Magnésio/administração & dosagem , Magnésio/uso terapêutico , Pessoa de Meia-Idade , Traumatismo por Reperfusão Miocárdica/prevenção & controle , Miocárdio/patologia , Fosfocreatina/administração & dosagem , Cloreto de Potássio/administração & dosagem , Cloreto de Potássio/uso terapêutico , Cloreto de Sódio/administração & dosagem , Cloreto de Sódio/uso terapêutico , Fatores de TempoRESUMO
OBJECTIVE: Myocardial protection with blood cardioplegia during cardiac surgery is increasingly preferred, but few studies have compared the protective effects of crystalloid cardioplegia to the same solution with blood as the only variable. This clinical study compared the protective effects of crystalloid or blood-based St. Thomas' Hospital cardioplegic solution No. 1. METHODS: Fifty higher risk patients undergoing elective coronary artery bypass surgery, with an ejection fraction less than 40%, were randomly allocated to receive cold (4 degrees C) intermittent crystalloid St. Thomas' No. 1 cardioplegia (n = 25), or a similar blood-based solution (n = 25) with a haematocrit of 10-12%. We determined (1) peri-operative and post-operative arrhythmias, (2) left and right ventricular function (24 h) using the thermodilution technique, (3) left ventricular high-energy phosphate content sampled before ischaemia, the end of ischaemia and the end of bypass. RESULTS: Pre-operative haemodynamic data, aortic cross-clamp and bypass times were similar in both groups of patients; there was no mortality. At the end of ischaemia there were no differences in ATP content between groups but creatine phosphate was maintained at a significantly (P < 0.007) higher level in the blood-based St. Thomas' cardioplegia group than the crystalloid St. Thomas' cardioplegia group (20+/-2 (SE) vs. 13+/-1 micromol/g dry wt, respectively). Return to spontaneous sinus rhythm was significantly (P = 0.002) increased in the blood-based St. Thomas' cardioplegia group (96%) compared to the crystalloid St. Thomas' cardioplegia group (60%). Early post-operative ventricular dysfunction occurred in both groups, but normal LV function (stroke work index) recovered significantly (P = 0.043) more rapidly (by 2 h) in the blood-based St. Thomas' cardioplegia group of patients. CONCLUSIONS: In a higher risk (EF < 40%) group of patients undergoing elective cardiac surgery, addition of blood to an established crystalloid cardioplegic solution significantly enhanced myocardial protection by reducing arrhythmias, improving rate of recovery of function and maintaining myocardial high-energy phosphate content during ischaemia.
Assuntos
Soluções Cardioplégicas , Parada Cardíaca Induzida/métodos , Substitutos do Plasma/uso terapêutico , Complicações Pós-Operatórias/prevenção & controle , Soluções para Reidratação/uso terapêutico , Nucleotídeos de Adenina/metabolismo , Idoso , Bicarbonatos/uso terapêutico , Cloreto de Cálcio/uso terapêutico , Soluções Cardioplégicas/uso terapêutico , Ponte de Artéria Coronária , Soluções Cristaloides , Eletrocardiografia , Feminino , Hemodinâmica/efeitos dos fármacos , Humanos , Período Intraoperatório , Soluções Isotônicas , Magnésio/uso terapêutico , Masculino , Pessoa de Meia-Idade , Isquemia Miocárdica/metabolismo , Isquemia Miocárdica/cirurgia , Miocárdio/metabolismo , Fosfocreatina/metabolismo , Cloreto de Potássio/uso terapêutico , Cloreto de Sódio/uso terapêutico , Resultado do TratamentoRESUMO
Severe volume depletion from diuresis can produce potentially life-threatening hypotension, coronary and cerebral insufficiency, and significant renal impairment. Appropriate precautions include initiating diuretics at low doses and monitoring patients closely. Metabolic alkalosis, another frequent side effect of diuretic therapy, can usually be diagnosed by near absence of chloride in the urine. Corrective agents used include potassium chloride and sodium chloride.